Table 2.
The baseline characteristics of the VR Patient Journey Trial.
| VR Group (n = 60) |
Control Group (n = 61) |
p-Value * | |
|---|---|---|---|
| Age (years) | 67.88 ± 8.56 | 67.08 ± 8.30 | 0.60 |
| Sex, male (%) | 48 (80) | 50 (82) | 0.82 |
| Cardiac surgery type | 0.36 | ||
| AVR | 12 (20) | 19 (31.2) | |
| AVR + MVR | 1 (1.7) | 1 (1.6) | |
| AVR + CABG | 9 (15) | 3 (4.9) | |
| AVR + TVR | 1 (1.7) | 0 (0.0) | |
| CABG | 27 (45) | 22 (36) | |
| CABG + MVR | 1 (1.7) | 0 (0.0) | |
| MVR + TVR + CABG | 1 (1.7) | 0 (0.0) | |
| MVR + TVR | 5 (8.3) | 9 (14.8) | |
| MV Replacement | 2 (3.3) | 6 (9.8) | |
| TV Replacement | 1 (1.7) | 1 (1.6) | |
| follow-up duration (days) | 23.5 (21) | 23 (24) | 0.77 |
Data are mean ± standard deviation, median with interquartile range (IQR), n (%). * Group differences were tested with the independent Student t-test, Mann–Whitney U-test or Chi-square test. VR = virtual reality, CABG = Coronary Artery Bypass Grafting, AVR = Aortic Valve Replacement, MVR = Mitral Valve Repair, MV Replacement = Mitral Valve Replacement, TVP = Tricuspid Valve Repair, TV Replacement = Tricuspid Valve Replacement, FU = follow-up.